Parvimonas micra-derived SirTM: An ADP-ribosyltransferase as a novel driver in colorectal cancer progression

Yuxiao Chang; Chao Yang; Fengyi Hou; Yubing Zhu; Ziran Huang; Likun Wang; Yuejiao Liu; Huan Zhang; Xiaoming Qin; Zikai Hao; Dong Li; Yafang Tan; Yinlan Bai; Lei Ding; Hong Gao; Fachao Zhi; Yun Zhang; Yujing Bi; Ruifu Yang

doi:10.1016/j.jare.2026.03.035

Key Points

The aim is to investigate how Parvimonas micra and its product SirTM influence colorectal cancer progression.
Examined the entry of P. micra into colorectal cancer cells.
Analyzed the release of SirTM and its effect on H2B modification.
Investigated the CEBPβ/SAA1/IL-17C signaling pathway.
P. micra modification of H2B through ADP-ribosylation was observed.
The interaction facilitated colorectal cancer cell development.
Key signaling pathways involved include CEBPβ, SAA1, and IL-17C.

Implication

Demonstrates that Parvimonas micra promotes colorectal cancer progression via a specific pathway.

Abstract

P. micra can enter CRC cells to release SirTM and modify H2B with ADP-ribosylation, thereby promoting the development of CRC through the CEBPβ/SAA1/IL-17C pathway.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Chang et al. (2026) studied this question.

synapsesocial.com/papers/69be34886e48c4981c672ba6 https://doi.org/10.1016/j.jare.2026.03.035

View Full Paper

Ask AI

Bookmark

Share

Parvimonas micra-derived SirTM: An ADP-ribosyltransferase as a novel driver in colorectal cancer progression

Key Points

Implication

Abstract

Discussion

Cite This Study

Parvimonas micra-derived SirTM: An ADP-ribosyltransferase as a novel driver in colorectal cancer progression

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading